Voyager Acquisition Corp. II is a SPAC — a blank check company with no operations or identified acquisition target. Voyager II raised $220M through an IPO of 22M units at $10.00 per unit, with proceeds held in a trust account until the company completes an acquisition or liquidates. Voyager II is targeting businesses in technology, fintech, and healthcare, though it is not restricted to these sectors. The sponsor, Voyager Acquisition Sponsor Holdco II LLC, acquired 5.5M founder shares for $25,000 total, representing 20% of post-IPO shares. This structure gives the sponsor highly asymmetric economics: the founder shares cost roughly $0.004 each but would be worth ~$10.00 per share upon deal completion, creating a strong incentive to complete a transaction regardless of deal quality. Public shareholders are protected by a redemption right worth roughly $10.00 per share from the trust, but face meaningful dilution from the founder shares and warrants if a deal is completed. Key figures include CEO Adeel Rouf, who has prior SPAC experience including a deal with Rubicon Technologies that ended in delisting, and Chairman Warren Hosseinion, a healthcare-focused executive whose prior SPAC was delisted after failing to complete a deal. The same team's predecessor vehicle, Voyager Acquisition Corp., raised $253M in 2024 and signed a deal with Veraxa Biotech in April 2025, which remained pending as of March 2026.